After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, ARVN falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Arvinas Inc is $601.75M. A total of 3.23 million shares were traded on the day, compared to an average of 1.63M shares.
In the most recent transaction, Berkowitz Noah sold 8,658 shares of ARVN for 8.59 per share on Mar 18 ’25. After the transaction, the Chief Medical Officer now owns 110,023 company shares. In a previous transaction on Mar 18 ’25, Noah Berkowitz bought 8,658 shares at 8.59 per share.
Among the insiders who sold shares, Loomis David K disposed of 1,214 shares on Feb 24 ’25 at a per-share price of $16.75. This resulted in the Chief Accounting Officer holding 18,863 shares of ARVN after the transaction. In another insider transaction, Cacace Angela M sold 4,207 shares at $16.70 per share on Feb 24 ’25. Company shares held by the Chief Scientific Officer now total 97,231.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, ARVN has a high of $44.85 and a low of $7.91.
As of this writing, ARVN has an earnings estimate of -$1.01 per share for the current quarter. EPS was calculated based on a consensus of 16.0 estimates, with a high estimate of -$0.51 per share and a lower estimate of -$1.58.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. ARVN’s latest balance sheet shows that the firm has $1.50B in Cash & Short Term Investments as of fiscal 2021. There were $5.00M in debt and $261.70M in liabilities at the time. Its Book Value Per Share was $8.16, while its Total Shareholder’s Equity was $781.70M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ARVN is Buy with a score of 4.55.
